JF
CYT

Jump Financial’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Jump Financial’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-21,300
Closed -$80K – 2115
2022
Q1 		$80K Buy
+21,300
New +$121K ﹤0.01% 1435

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jump Financial's CYT Position: Q2 2022 in Review

Jump Financial sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q2 2022, closing a stake of 21,300 shares — an estimated $80K sold.

Jump Financial first reported a position in CYT in Q1 2022 and held it in 1 quarter. The position peaked at $80K in Q1 2022. 45 funds tracked by Wall St. Rank hold CYT as of Q2 2022.

  • Jump Financial reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Jump Financial sold 21,300 Cyteir Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $80K.
  • Jump Financial first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Jump Financial's Cyteir Therapeutics, Inc. Common Stock position peaked at $80K in Q1 2022.
  • 45 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Jump Financial's 13F filing for Q2 2022, filed 9 Aug 2022.